These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17630947)

  • 1. Management of cardiovascular risk factors in patients with metabolic syndrome.
    de la Sierra A; Ruilope LM
    Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):209-14. PubMed ID: 17630947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical significance of metabolic syndrome in hypertension: metabolic syndrome increases cardiovascular risk : the pro position.
    de la Sierra A
    High Blood Press Cardiovasc Prev; 2008 Apr; 15(2):53-7. PubMed ID: 23334872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
    Shepherd J; Betteridge J; Van Gaal L;
    Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug treatment of metabolic syndrome.
    Altabas V
    Curr Clin Pharmacol; 2013 Aug; 8(3):224-31. PubMed ID: 22950955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacological management of metabolic syndrome.
    Rask Larsen J; Dima L; Correll CU; Manu P
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):397-410. PubMed ID: 29345505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome, inflammation and atherosclerosis.
    Paoletti R; Bolego C; Poli A; Cignarella A
    Vasc Health Risk Manag; 2006; 2(2):145-52. PubMed ID: 17319458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Components of the metabolic syndrome among a sample of overweight and obese Costa Rican schoolchildren.
    Holst-Schumacher I; Nuñez-Rivas H; Monge-Rojas R; Barrantes-Santamaría M
    Food Nutr Bull; 2009 Jun; 30(2):161-70. PubMed ID: 19689095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
    Després JP
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].
    Vanuzzo D; Pilotto L; Mirolo R; Pirelli S
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):6S-17S. PubMed ID: 18773746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing cardiovascular risk in patients with metabolic syndrome.
    Bassand JP
    Clin Cornerstone; 2006; 8 Suppl 1():S7-14. PubMed ID: 16903164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should the insulin resistance syndrome be treated in the elderly?
    Grant RW; Meigs JB
    Drugs Aging; 2004; 21(3):141-51. PubMed ID: 14979733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome: diagnosis and treatment.
    Zieve FJ
    Clin Cornerstone; 2004; 6 Suppl 3():S5-13. PubMed ID: 15707265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome.
    Bestermann W; Houston MC; Basile J; Egan B; Ferrario CM; Lackland D; Hawkins RG; Reed J; Rogers P; Wise D; Moore MA
    Am J Med Sci; 2005 Jun; 329(6):292-305. PubMed ID: 15958871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
    Rosenson RS
    Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.